120 related articles for article (PubMed ID: 10637007)
1. Localization of experimental submucosal esophageal tumor in rabbits by using mono-L-aspartyl chlorin e6 and long-wavelength photodynamic excitation.
Sheyhedin I; Okunaka T; Kato H; Yamamoto Y; Sakaniwa N; Konaka C; Aizawa K
Lasers Surg Med; 2000; 26(1):83-9. PubMed ID: 10637007
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
3. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
Wong TW; Aizawa K; Sheyhedin I; Wushur C; Kato H
J Pharmacol Sci; 2003 Oct; 93(2):136-42. PubMed ID: 14578580
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6.
Katsumi TA; Aizawa K; Kuroiwa Y; Saito K; Kurata Y; Ii Y; Okunaka T; Konaka C; Kato H
Photochem Photobiol; 1996 Oct; 64(4):671-5. PubMed ID: 8863472
[TBL] [Abstract][Full Text] [Related]
6. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
Mori K; Ohta M; Sano A; Yoneya S; Sonoda M; Kaneda A; Sato Y
Nippon Ganka Gakkai Zasshi; 1997 Feb; 101(2):134-40. PubMed ID: 9124093
[TBL] [Abstract][Full Text] [Related]
7. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
9. Transadventitial localisation of atheromatous plaques by fluorescence emission spectrum analysis of mono-L-aspartyl chlorin e6.
Hayashi J; Kuroiwa Y; Sato H; Saito T; Aizawa K
Cardiovasc Res; 1993 Nov; 27(11):1943-7. PubMed ID: 8287401
[TBL] [Abstract][Full Text] [Related]
10. Phase-resolved fluorescence study of mono-L-aspartyl chlorin E6.
Li L; Kodama K; Saito K; Aizawa K
J Photochem Photobiol B; 2002 May; 67(1):51-6. PubMed ID: 12007467
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy using mono-L-aspartyl chlorin e6 for rabbit experimental hepatoma.
Nakamura J; Kajiwara H
J Hepatobiliary Pancreat Surg; 1999; 6(3):312-9. PubMed ID: 10526068
[TBL] [Abstract][Full Text] [Related]
12. Intraocular biodistribution of mono-L-aspartyl chlorin e6 in a primate choroidal neovascularization model.
Mori K; Kanai K; Peyman GA; Yoneya S
Ophthalmic Surg Lasers Imaging; 2007; 38(2):142-7. PubMed ID: 17396695
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence properties of a hydrophilic sensitizer in pigmented rats, rabbits, and monkeys.
Moshfeghi D; Peyman GA; Kazi AA; Unal M; Khoobehi B; Yoneya S; Mori K
Ophthalmic Surg Lasers; 1999; 30(9):750-3. PubMed ID: 10574497
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6.
Mori K; Yoneya S; Anzail K; Kabasawa S; Sodeyama T; Peyman GA; Moshfeghi DM
Retina; 2001; 21(5):499-508. PubMed ID: 11642380
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
17. Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
Spikes JD; Bommer JC
J Photochem Photobiol B; 1993 Feb; 17(2):135-43. PubMed ID: 8459317
[TBL] [Abstract][Full Text] [Related]
18. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessels and its contribution to the antitumor effect.
Saito K; Mikuniya N; Aizawa K
Jpn J Cancer Res; 2000 May; 91(5):560-5. PubMed ID: 10835502
[TBL] [Abstract][Full Text] [Related]
19. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6).
Mori K; Yoneya S; Ohta M; Sano A; Anzai K; Peyman GA; Moshfeghi DM
Ophthalmology; 1999 Jul; 106(7):1384-91. PubMed ID: 10406627
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy using a diode laser with mono-L-aspartyl chlorin e6 for implanted fibrosarcoma in mice.
Katsumi T; Aizawa K; Okunaka T; Kuroiwa Y; Ii Y; Saito K; Konaka C; Kato H
Jpn J Cancer Res; 1994 Nov; 85(11):1165-70. PubMed ID: 7829403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
